ESMO 2022 | Genitourinary cancer highlights at ESMO 2022
Enrique Grande, MD, PhD, MSc, MD Anderson Cancer Center Madrid, Madrid, Spain, provides an overview of his highlights presented at the European Society for Medical Oncology (ESMO) 2022 Congress in the field of genitourinary cancer, including updates in PD-L1 testing and adjuvant therapy in urothelial cancer. Dr Grande additionally comments on the Phase III PIVOT-09 trial (NCT03729245) of nivolumab and an interleukin-2 prodrug, which was inferior to the investigator’s choice of treatment. This interview took place at the ESMO 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
This ESMO meeting has been extremely excited for all of those that are treating genitourinary tumors. In these ESMO meetings, we have seen up to five Phase III trials in the field of RCC or bladder cancer. So I think this is impressive, very good data about biomarkers, about the SP142 testing. How we are calling patients PD-1 or not.
We have seen a positive Phase III trial showing that triplets in metastatic renal carcinoma first line are impacting in the progression of the survival...
This ESMO meeting has been extremely excited for all of those that are treating genitourinary tumors. In these ESMO meetings, we have seen up to five Phase III trials in the field of RCC or bladder cancer. So I think this is impressive, very good data about biomarkers, about the SP142 testing. How we are calling patients PD-1 or not.
We have seen a positive Phase III trial showing that triplets in metastatic renal carcinoma first line are impacting in the progression of the survival. The primary endpoint be doublet of immunotherapy. So very exciting data and very challenging data in the adjuvant field. Unfortunately, three Phase III trials did not impact in the disease visual survival primary endpoint with atezolizumab or nivolumab or nivolumab-ipilimumab for the adjuvant treatment, a lot of food for thoughts in the field of adjuvant treatment, perioperative systemic management treatment.
Another one, the PIVOT IO 009 trial presented by Dr. Nazir Tannir unfortunately did not show an impact of the combination of nivolumab plus new design interleukin-2 compound versus standard tyrosine kinase inhibitor. So immunotherapy is working, but we need to select patients, the best patients for each of these strategies.
Read more...
